Dolinschek R, Hingerl J, Benge A, Zafiu C, Schuren E, Ehmoser E
Mol Oncol. 2020; 15(2):503-522.
PMID: 33155399
PMC: 7858284.
DOI: 10.1002/1878-0261.12845.
Gu H, Zhou B
Oncol Lett. 2018; 15(5):6225-6232.
PMID: 29849782
PMC: 5962868.
DOI: 10.3892/ol.2018.8152.
Benzina S, Harquail J, Guerrette R, OBrien P, Jean S, Crapoulet N
J Cancer. 2017; 7(14):2035-2044.
PMID: 28070224
PMC: 5219892.
DOI: 10.7150/jca.15200.
Fan Y, Qu X, Ma Y, Liu Y, Hu X
Oncol Lett. 2016; 12(2):1113-1118.
PMID: 27446403
PMC: 4950184.
DOI: 10.3892/ol.2016.4730.
Hernandez-Corbacho M, Canals D, Adada M, Liu M, Senkal C, Yi J
J Biol Chem. 2015; 290(42):25356-73.
PMID: 26318452
PMC: 4646185.
DOI: 10.1074/jbc.M115.658658.
Targeting the p53 pathway.
Golubovskaya V, Cance W
Surg Oncol Clin N Am. 2013; 22(4):747-64.
PMID: 24012397
PMC: 3810242.
DOI: 10.1016/j.soc.2013.06.003.
Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics.
Cance W, Kurenova E, Marlowe T, Golubovskaya V
Sci Signal. 2013; 6(268):pe10.
PMID: 23532331
PMC: 3693475.
DOI: 10.1126/scisignal.2004021.
Nanog increases focal adhesion kinase (FAK) promoter activity and expression and directly binds to FAK protein to be phosphorylated.
Ho B, Olson G, Figel S, Gelman I, Cance W, Golubovskaya V
J Biol Chem. 2012; 287(22):18656-73.
PMID: 22493428
PMC: 3365765.
DOI: 10.1074/jbc.M111.322883.
FAK and p53 protein interactions.
Golubovskaya V, Cance W
Anticancer Agents Med Chem. 2011; 11(7):617-9.
PMID: 21355845
PMC: 3184193.
DOI: 10.2174/187152011796817619.
Focal adhesion kinase and p53 signal transduction pathways in cancer.
Golubovskaya V, Cance W
Front Biosci (Landmark Ed). 2010; 15(3):901-12.
PMID: 20515733
PMC: 3136041.
DOI: 10.2741/3653.
Ethanol enhances the interaction of breast cancer cells over-expressing ErbB2 with fibronectin.
Xu M, Bower K, Chen G, Shi X, Dong Z, Ke Z
Alcohol Clin Exp Res. 2010; 34(5):751-60.
PMID: 20201928
PMC: 4981247.
DOI: 10.1111/j.1530-0277.2010.01147.x.
Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma.
Beierle E, Ma X, Stewart J, Nyberg C, Trujillo A, Cance W
Cell Cycle. 2010; 9(5):1005-15.
PMID: 20160475
PMC: 2855768.
DOI: 10.4161/cc.9.5.10936.
Suppression of human MDA-MB-435S tumor by U6 promoter-driven short hairpin RNAs targeting focal adhesion kinase.
Huang A, Wan Y, Liao D, Hu H, Wei L, Wang X
J Cancer Res Clin Oncol. 2010; 136(8):1229-42.
PMID: 20140743
DOI: 10.1007/s00432-010-0773-3.
Focal adhesion kinase as an immunotherapeutic target.
Kobayashi H, Azumi M, Kimura Y, Sato K, Aoki N, Kimura S
Cancer Immunol Immunother. 2008; 58(6):931-40.
PMID: 18941742
PMC: 2664392.
DOI: 10.1007/s00262-008-0608-0.
Focal adhesion kinase versus p53: apoptosis or survival?.
Cance W, Golubovskaya V
Sci Signal. 2008; 1(20):pe22.
PMID: 18493017
PMC: 4560103.
DOI: 10.1126/stke.120pe22.
A systems biology approach for pathway level analysis.
Draghici S, Khatri P, Tarca A, Amin K, Done A, Voichita C
Genome Res. 2007; 17(10):1537-45.
PMID: 17785539
PMC: 1987343.
DOI: 10.1101/gr.6202607.
Cis-hydroxyproline-induced inhibition of pancreatic cancer cell growth is mediated by endoplasmic reticulum stress.
Mueller C, Emmrich J, Jaster R, Braun D, Liebe S, Sparmann G
World J Gastroenterol. 2006; 12(10):1569-76.
PMID: 16570349
PMC: 4124289.
DOI: 10.3748/wjg.v12.i10.1569.
Construction of retroviral vector of p(125FAK) specific ribozyme genes and its effects on BGC-823 cells.
Guan G, Jian H, Lei D, Lu H, Zhang X
World J Gastroenterol. 2006; 12(5):686-90.
PMID: 16521179
PMC: 4066116.
DOI: 10.3748/wjg.v12.i5.686.
Specific induction of pp125 focal adhesion kinase in human breast cancer.
Watermann D, Gabriel B, Jager M, Orlowska-Volk M, Hasenburg A, Hausen A
Br J Cancer. 2005; 93(6):694-8.
PMID: 16136050
PMC: 2361616.
DOI: 10.1038/sj.bjc.6602744.
Entamoeba histolytica: focal adhesion kinase and Erk phosphorylation are altered in the cytoskeleton mutant BG-3.
Robledo T, Cruz-Vera J, Reyes M, de la Garza M, Ortega A, Salazar E
Parasitol Res. 2005; 95(4):231-5.
PMID: 15729589
DOI: 10.1007/s00436-004-1290-6.